Aptose Biosciences Files 8-K on Financials
Ticker: APTOF · Form: 8-K · Filed: Aug 13, 2025 · CIK: 882361
Sentiment: neutral
Topics: financial-condition, results-of-operations, company-history
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Aug 13, 2025, detailing financial condition & results. Check it out.
AI Summary
Aptose Biosciences Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the biological products sector.
Why It Matters
This 8-K filing provides investors with crucial updates on Aptose Biosciences Inc.'s financial performance and operational status, enabling informed investment decisions.
Risk Assessment
Risk Level: medium — As a biotechnology company, Aptose Biosciences Inc. is subject to inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- August 13, 2025 (date) — Date of earliest event reported
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- Canada (location) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is to report on Aptose Biosciences Inc.'s Results of Operations and Financial Condition, and includes Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 13, 2025.
What were Aptose Biosciences Inc.'s previous names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which state is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
What is the Standard Industrial Classification for Aptose Biosciences Inc.?
The Standard Industrial Classification for Aptose Biosciences Inc. is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2025-08-13 17:00:34
Filing Documents
- f8k_081325.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 58KB
- 0001171843-25-005383.txt ( ) — 273KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_081325_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 13, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated August 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: August 13, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer